EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs

Steven M Nederveld iD, Matthew J Krautmann, John Mitchell

Journal of Veterinary Pharmacology and Therapeutics · 2025

DOI: 10.1111/jvp.13503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2025. Verfasst von Steven M Nederveld und 2 weiteren Autor:innen. Beteiligte Einrichtung: Zoetis, Parsippany-Troy Hills, New Jersey, USA. Hauptthemen laut MEDLINE: Pyrimidines, Sulfonamides, Dog Diseases, Janus Kinase 1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zoetis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apoquel(oclacitinib maleate) as a film‐coated tablet, a selective Janus kinase (JAK)1 inhibitor, was approved by the United States Food and Drug Administration (FDA) in 2013 for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. The goal of this review is to describe the safety of oclacitinib in dogs based on data from investigational laboratory and field studies, independent directed studies, and an extensive postmarketing pharmacovigilance (PV) surveillance program. The safety of oclacitinib has been extensively evaluated in investigational and independent studies. In the oclacitinib postapproval PV surveillance, the types and rank order of frequency of reported adverse events were similar to the premarketing field studies, with diarrhea, anorexia, and lethargy being the most frequently reported adverse events. In the postmarketing PV continuous monitoring, adverse events for patients receiving oclacitinib are rarely reported and the individual clinical signs within the PV adverse event reports were considered “very rare” in frequency. An age‐ and breed‐ matched retrospective cohort study in dogs with allergic dermatitis showed no significant difference in incidence of neoplasia between dogs treated with oclacitinib and dogs treated with other systemic therapies. The extensive investigational and PV experience with oclacitinib shows that long‐term or lifelong use per label instructions has a positive benefit–risk profile and is not associated with any cumulative safety risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesSulfonamidesDog DiseasesJanus Kinase 1AnimalsDogsDermatitis, Atopic

Stichwörter der Autor:innen

JAK1 selective inhibitoradverse eventsallergic dermatitisatopic dermatitisdogsoclacitinibpharmacovigilancesafety

Substanzen

PyrimidinesSulfonamidesoclacitinibJanus Kinase 1

Autor:innen und Institutionen

  • Zoetis, Parsippany-Troy Hills, New Jersey, USA.
  • Zoetis (Retired), Parsippany-Troy Hills, New Jersey, USA.

ORCID-Profile: Steven M Nederveld

Förderung

  • Zoetis

Zitieren

APA

Nederveld, S. M., Krautmann, M. J., & Mitchell, J. (2025). Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13503

Vancouver

Nederveld SM, Krautmann MJ, Mitchell J. Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs. Journal of Veterinary Pharmacology and Therapeutics. 2025. doi:10.1111/jvp.13503

BibTeX
@article{Nederveld2025,
  author = {Nederveld, Steven M and Krautmann, Matthew J and Mitchell, John},
  title = {Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.1111/jvp.13503}
}
Kostenlos starten →